The Landau Lab develops computational and experimental tools to study cancer evolution. Our research is geared towards uncovering basic principles in evolutionary biology, using both patient derived samples and experimental systems for modeling cancer evolution. In addition, we seek to apply this knowledge to designing the next generation of precision medicine tools to overcome cancer evolution, as a central challenge to cancer cure today.
+Dan Landau, MD, PhD
Dan A. Landau, MD, PhD, is a Core Member and Assistant Investigator at the New York Genome Center. He holds a joint appointment as Assistant Professor of Medicine in the Division of Hematology and Medical Oncology & the Department of Physiology and Biophysics at Weill Cornell Medicine.
Dr. Landau’s lab is working to discover fundamental principals in evolutionary biology and biological regulation of human cancer cells. The ultimate goal is to understand the basic dimensions that determine cancer’s evolution, in order to devise therapies that directly anticipate and address it.
Dr. Landau grew up in Tel Aviv, Israel where he obtained his MD from Tel Aviv University. He then went on to receive his PhD from Paris Diderot University in Paris, France. His most recent position was an Instructor of Medicine at Harvard Medical School, working at the Dana Farber Cancer Institute and the Broad Institute.
Dr. Landau has pioneered the study of intra-tumoral genetic and epigenetic diversity in patient samples, to enable the study of cancer evolution in its natural environment. His work was recognized with many honors including the Burroughs Wellcome Fund Career Award for Medical Scientists as well as the K01 award from the NIH Big Data to Knowledge initiative.
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S.
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassenti LZ, Ghia EM, Kipps TJ, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla SA, Aster JC, Reed R, DeLuca DS, Brown JR, Neuberg D, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ.
Mutations driving CLL and their evolution in progression and relapse.
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ.
- Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.